Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669332 | 0.80 | MAPT (0.57) | MAOBCYP3A4CYP2A6MAPTALDH1A1 | |
| SCHEMBL20530567 | 0.79 | MAOB (0.49) | MAOBTXNRD1TXNRD3TXNRD2CYP3A4 | |
| SCHEMBL18470241 | 0.78 | CA2 (0.46) | MAOBTXNRD1TXNRD3TXNRD2CYP3A4 | |
| SCHEMBL20530571 | 0.77 | CYP3A4 (0.49) | MAOBCYP3A4CYP2A6MAPTMEN1 | |
| SCHEMBL11883080 | 0.77 | MEN1 (0.48) | CYP3A4MAPTMEN1ALDH1A1DNMT1 | |
| SCHEMBL18335399 | 0.76 | CYP3A4 (0.41) | MAOBCYP1A1CYP1A2CYP2B6CYP3A4 | |
| SCHEMBL20530584 | 0.74 | MAOB (0.46) | MAOBCYP1A1CYP1A2MAPTHPGD | |
| SCHEMBL2204213 | 0.73 | HTR1B (0.55) | MAOBCYP1A2CYP3A4CYP2A6MEN1 | |
| SCHEMBL30000708 | 0.73 | HTR1B (0.55) | MAOBCYP1A2CYP3A4CYP2A6MEN1 | |
| SCHEMBL10347560 | 0.72 | MAPT (0.56) | MAOBCYP3A4CYP2A6MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117873-B2 | Oxazine compound, composition, and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11117872-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11028059-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-06-08 | — | — | US | disclosed |
| CN-108368217-B | Oxazine compound, composition and cured product | DIC株式会社 | 2021-05-07 | — | — | CN | disclosed |
| CN-108368218-B | Oxazine compound, composition and cured product | DIC株式会社 | 2020-11-06 | — | — | CN | disclosed |
| CN-108368216-B | Oxazine compound, composition and cured product | DIC株式会社 | 2020-09-18 | — | — | CN | disclosed |
| US-20180362480-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180362478-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180362477-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388461-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388460-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388459-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028059-B2 | Oxazine compound, composition and cured product | KDM5A, WDR5, RNF5 | MAOB 1747/4885TXNRD1 3520/4885TXNRD3 3848/4885 |
| US-20180362480-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | KDM5A, WDR5, SMC4 | MAOB 1509/4885TXNRD1 3327/4885TXNRD3 3699/4885 |
| US-20180362478-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, WDR5, RNF5 | MAOB 1731/4885TXNRD1 3492/4885TXNRD3 3827/4885 |
| US-11117873-B2 | Oxazine compound, composition, and cured product | KDM5A, WDR5, SMC4 | MAOB 1509/4885TXNRD1 3327/4885TXNRD3 3699/4885 |
| US-11117872-B2 | Oxazine compound, composition and cured product | KDM5A, WDR5, RNF5 | MAOB 1731/4885TXNRD1 3492/4885TXNRD3 3827/4885 |
| US-20180362477-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, WDR5, RNF5 | MAOB 1747/4885TXNRD1 3520/4885TXNRD3 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.